Reinforcement learning as an intermediate phenotype in psychosis? Deficits sensitive to illness stage but not associated with polygenic risk of schizophrenia in the general population.


Journal

Schizophrenia research
ISSN: 1573-2509
Titre abrégé: Schizophr Res
Pays: Netherlands
ID NLM: 8804207

Informations de publication

Date de publication:
08 2020
Historique:
received: 11 06 2019
revised: 20 01 2020
accepted: 19 04 2020
pubmed: 12 5 2020
medline: 22 6 2021
entrez: 12 5 2020
Statut: ppublish

Résumé

Schizophrenia is a complex disorder in which the causal relations between risk genes and observed clinical symptoms are not well understood and the explanatory gap is too wide to be clarified without considering an intermediary level. Thus, we aimed to test the hypothesis of a pathway from molecular polygenic influence to clinical presentation occurring via deficits in reinforcement learning. We administered a reinforcement learning task (Go/NoGo) that measures reinforcement learning and the effect of Pavlovian bias on decision making. We modelled the behavioural data with a hierarchical Bayesian approach (hBayesDM) to decompose task performance into its underlying learning mechanisms. Study 1 included controls (n = 29, F|M = 0.81), At Risk Mental State for psychosis (ARMS, n = 23, F|M = 0.35) and FEP (First-episode psychosis, n = 26, F|M = 0.18). Study 2 included healthy adolescents (n = 735, F|M = 1.06), 390 of whom had their polygenic risk scores for schizophrenia (PRSs) calculated. Patients with FEP showed significant impairments in overriding Pavlovian conflict, a lower learning rate and a lower sensitivity to both reward and punishment. Less widespread deficits were observed in ARMS. PRSs did not significantly predict performance on the task in the general population, which only partially correlated with measures of psychopathology. Reinforcement learning deficits are observed in first episode psychosis and, to some extent, in those at clinical risk for psychosis, and were not predicted by molecular genetic risk for schizophrenia in healthy individuals. The study does not support the role of reinforcement learning as an intermediate phenotype in psychosis.

Sections du résumé

BACKGROUND
Schizophrenia is a complex disorder in which the causal relations between risk genes and observed clinical symptoms are not well understood and the explanatory gap is too wide to be clarified without considering an intermediary level. Thus, we aimed to test the hypothesis of a pathway from molecular polygenic influence to clinical presentation occurring via deficits in reinforcement learning.
METHODS
We administered a reinforcement learning task (Go/NoGo) that measures reinforcement learning and the effect of Pavlovian bias on decision making. We modelled the behavioural data with a hierarchical Bayesian approach (hBayesDM) to decompose task performance into its underlying learning mechanisms. Study 1 included controls (n = 29, F|M = 0.81), At Risk Mental State for psychosis (ARMS, n = 23, F|M = 0.35) and FEP (First-episode psychosis, n = 26, F|M = 0.18). Study 2 included healthy adolescents (n = 735, F|M = 1.06), 390 of whom had their polygenic risk scores for schizophrenia (PRSs) calculated.
RESULTS
Patients with FEP showed significant impairments in overriding Pavlovian conflict, a lower learning rate and a lower sensitivity to both reward and punishment. Less widespread deficits were observed in ARMS. PRSs did not significantly predict performance on the task in the general population, which only partially correlated with measures of psychopathology.
CONCLUSIONS
Reinforcement learning deficits are observed in first episode psychosis and, to some extent, in those at clinical risk for psychosis, and were not predicted by molecular genetic risk for schizophrenia in healthy individuals. The study does not support the role of reinforcement learning as an intermediate phenotype in psychosis.

Identifiants

pubmed: 32389614
pii: S0920-9964(20)30229-2
doi: 10.1016/j.schres.2020.04.022
pmc: PMC7594641
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

389-396

Subventions

Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_G0802534
Pays : United Kingdom

Informations de copyright

Copyright © 2020 The Authors. Published by Elsevier B.V. All rights reserved.

Références

Front Psychiatry. 2013 Dec 23;4:172
pubmed: 24391603
Neuroimage. 2012 Aug 1;62(1):154-66
pubmed: 22548809
Neuropsychopharmacology. 2018 Jul;43(8):1691-1699
pubmed: 29748629
Arch Gen Psychiatry. 2012 Feb;69(2):129-38
pubmed: 22310503
PLoS One. 2016 Apr 04;11(4):e0152781
pubmed: 27044008
Int J Epidemiol. 2018 Feb 1;47(1):18-19g
pubmed: 29177462
Br J Psychiatry. 1995 Jul;167(1):99-103
pubmed: 7551619
Brain. 2016 Oct;139(Pt 10):2600-2608
pubmed: 27543973
Mol Psychiatry. 2008 Mar;13(3):239, 267-76
pubmed: 17684497
Brain. 2019 Feb 1;142(2):471-485
pubmed: 30535067
BMJ. 2012 Apr 05;344:e2233
pubmed: 22491790
Schizophr Bull. 2016 Nov;42(6):1476-1485
pubmed: 27179125
J Neurophysiol. 2015 Jun 1;113(10):3459-61
pubmed: 25185818
Schizophr Res. 2008 Sep;104(1-3):279-86
pubmed: 18562177
Proc Natl Acad Sci U S A. 2016 Aug 9;113(32):9105-10
pubmed: 27457931
Comput Psychiatr. 2017 Oct 01;1:24-57
pubmed: 29601060
JAMA Psychiatry. 2016 Mar;73(3):221-8
pubmed: 26818099
Nature. 2014 Jul 24;511(7510):421-7
pubmed: 25056061
PLoS Biol. 2016 Nov 10;14(11):e2000638
pubmed: 27832071
Psychol Aging. 2016 Nov;31(7):747-757
pubmed: 27599017
Schizophr Bull. 1987;13(2):261-76
pubmed: 3616518
PLoS Comput Biol. 2018 Dec 31;14(12):e1006679
pubmed: 30596638
Schizophr Bull. 2008 Sep;34(5):835-47
pubmed: 18591195
Biol Psychiatry Cogn Neurosci Neuroimaging. 2017 Nov;2(8):680-688
pubmed: 29560902
JAMA Psychiatry. 2016 Aug 1;73(8):852-61
pubmed: 27384424
Schizophr Bull. 1991;17(4):555-64
pubmed: 1805349
JAMA Psychiatry. 2014 May;71(5):531-9
pubmed: 24622944
Psychol Med. 2018 Aug;48(11):1909-1914
pubmed: 29233195
Aust N Z J Psychiatry. 2005 Nov-Dec;39(11-12):964-71
pubmed: 16343296
Nat Genet. 2018 Mar;50(3):381-389
pubmed: 29483656
Nat Rev Neurosci. 2015 May;16(5):278-89
pubmed: 25873038
Schizophr Bull. 2019 Mar 7;45(2):405-414
pubmed: 29608775
Schizophr Bull. 2004;30(4):1005-22
pubmed: 15954204
Nature. 2009 Aug 6;460(7256):748-52
pubmed: 19571811
Biol Psychiatry. 2000 Feb 1;47(3):210-20
pubmed: 10682218
J Am Acad Child Adolesc Psychiatry. 1988 Nov;27(6):726-37
pubmed: 3058677
Schizophr Bull. 2008 Nov;34(6):1008-11
pubmed: 18791075
Cogn Behav Neurol. 2004 Mar;17(1):32-40
pubmed: 15209223
Psychol Med. 2018 Jan;48(2):327-336
pubmed: 28641601

Auteurs

Marcella Montagnese (M)

Department of Psychiatry, University of Cambridge, United Kingdom.

Franziska Knolle (F)

Department of Psychiatry, University of Cambridge, United Kingdom.

Joost Haarsma (J)

Department of Psychiatry, University of Cambridge, United Kingdom.

Juliet D Griffin (JD)

Department of Psychiatry, University of Cambridge, United Kingdom.

Alex Richards (A)

MRC Centre for Neuropsychiatric Genetics and Genomics, Cardiff University, UK.

Petra E Vertes (PE)

Department of Psychiatry, University of Cambridge, United Kingdom.

Beatrix Kiddle (B)

Department of Psychiatry, University of Cambridge, United Kingdom.

Paul C Fletcher (PC)

Department of Psychiatry, University of Cambridge, United Kingdom; Wellcome Trust MRC Institute of Metabolic Science, Cambridge, Biomedical Campus, United Kingdom; Cambridgeshire and Peterborough National Health Service Foundation Trust, Cambridge,United Kingdom.

Peter B Jones (PB)

Department of Psychiatry, University of Cambridge, United Kingdom; Cambridgeshire and Peterborough National Health Service Foundation Trust, Cambridge,United Kingdom.

Michael J Owen (MJ)

MRC Centre for Neuropsychiatric Genetics and Genomics, Cardiff University, UK.

Peter Fonagy (P)

Research Department of Clinical, Educational and Health Psychology, University College London, United Kingdom.

Edward T Bullmore (ET)

Department of Psychiatry, University of Cambridge, United Kingdom; Behavioural and Clinical Neuroscience Institute, University of Cambridge, United Kingdom; Cambridgeshire and Peterborough National Health Service Foundation Trust, Cambridge,United Kingdom.

Raymond J Dolan (RJ)

Max Planck University College London Centre for Computational Psychiatry and Ageing Research, United Kingdom; Wellcome Centre for Human Neuroimaging, University College London, United Kingdom.

Michael Moutoussis (M)

Max Planck University College London Centre for Computational Psychiatry and Ageing Research, United Kingdom; Wellcome Centre for Human Neuroimaging, University College London, United Kingdom.

Ian M Goodyer (IM)

Department of Psychiatry, University of Cambridge, United Kingdom; Cambridgeshire and Peterborough National Health Service Foundation Trust, Cambridge,United Kingdom.

Graham K Murray (GK)

Department of Psychiatry, University of Cambridge, United Kingdom; Behavioural and Clinical Neuroscience Institute, University of Cambridge, United Kingdom; Cambridgeshire and Peterborough National Health Service Foundation Trust, Cambridge,United Kingdom. Electronic address: gm285@cam.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH